Dr Parveen Ahlawat - Academia.edu (original) (raw)
Uploads
Papers by Dr Parveen Ahlawat
Annals of pancreatic cancer, May 1, 2024
Radiotherapy and Oncology, Aug 1, 2021
Indian Journal of Nuclear Medicine, Dec 31, 2022
Annals of Oncology, Sep 1, 2021
Radiotherapy and Oncology, Aug 1, 2021
Radiotherapy and Oncology, Dec 1, 2019
Radiotherapy and Oncology, Aug 1, 2021
Radiotherapy and Oncology, Aug 1, 2021
Radiotherapy and Oncology, Aug 1, 2021
Radiotherapy and Oncology, Aug 1, 2021
Radiotherapy and Oncology, Aug 1, 2021
International Journal of Radiation Oncology Biology Physics, Nov 1, 2021
PURPOSE/OBJECTIVE(S) The incidence of de-novo metastatic head and neck (mHNC) has increased over ... more PURPOSE/OBJECTIVE(S) The incidence of de-novo metastatic head and neck (mHNC) has increased over time with the use of more sensitive metastatic work-up. With early diagnosis and better systemic therapies, aggressive management of mHNC has led to next most logical step in the management; use of definitive locoregional radiotherapy (d-RT) for patient responding to systemic therapy MATERIALS/METHODS: The institutional database was reviewed from January 2015 - March 2018, 5,483 HNC patients were isolated. Forty-nine patients were identified with de-novo mHNC, of which data was available for 31. Survival-analysis with endpoints of overall survival (OS) and progression free survival (PFS) was done. RESULTS With a median follow-up of 15 months, the median OS and PFS for the entire cohort was 15 and 7 months, respectively. Median PFS and OS of patients receiving d-RT vs no d-RT was 18 (range 14.97 - 21.03) months vs 5 (range 3.52 - 6.48) months, P = 0.005 and 38 (range 8.40 - 67.60) months vs 9 (range 4.56 - 13.45) months, P = 0.002, respectively. Patients with extra-pulmonary metastases had worse median OS of 21 (range 0 - 44.15) months, P = 0.047. CONCLUSION De-novo mHNC is a less often encountered diagnoses. Patients with extra-pulmonary metastases tend to do worse. However, patients who initially respond to chemotherapy fair better especially with d-RT. A prospective trial for such a clinical scenario would be unlikely and more retrospective evidence is needed for confirming OS and PFS advantage of using d-RT in such a setting.
Radiotherapy and Oncology, 2020
Radiotherapy and Oncology, 2021
Radiotherapy and Oncology, 2021
Radiotherapy and Oncology, 2021
Asian journal of oncology, Jul 1, 2016
with CTRT in the patients of uterine cervix of a tertiary cancer care centre. Patients and Method... more with CTRT in the patients of uterine cervix of a tertiary cancer care centre. Patients and Methods: Retrospective study was performed in locally advanced/advance stage patients of cervix UTERI registered in the institute between years 2009 to 2013. Patients were included in the two groups, group A consists of 89 patients who have received NACT + RS and 67 patients in group B who have received CTRT. Clinical records were reviewed with particular reference to presenting complaint, clinical stage, response to the therapy, disease free survival and overall survival. Statistical analysis was done using SPSS version 22. Results: In the neoadjuvant group (group A) (n=89) the median age of patients was 53 years (range 31-80 years), most of the patients (70%) were presented with complaint of postmenopausal bleeding. Of the total patients, 69 (77.5%) underwent to radical surgery and 5 (8.5%) received radiotherapy after NACT. From 69 patients, who had undergone to surgery, 54 (78.3%) had also received radiation. The overall response to induction chemotherapy was 84%. In the chemo radiation group (group B) (n=65) median age was 56 years (33-75 years). Vaginal bleeding (34%) followed by postmenopausal bleeding (32%) was major presenting complaint in this group. Overall response to the complete treatment was 91%. The median follow up time was 14.3 months in group A and 12.2 months in group B. The disease free survival for NACT group was 32 months (95% CI 26.8-36.5) whereas for CTRT group it was 28 months (95% CI 23.5-33) with 12 and 13 recurrences per group (p = .226). In NACT group overall survival was 46.2 months (95% CI 44-48.3) and for CTRT group it was 38.3 months (95%CI 36.6-40) with 3 and 2 deaths per group (p=.883). Conclusion: Present study shows comparable results, with no difference in survival between both the groups. However, NACT + RS group had showed better disease free and overall survival than another group. Further studies should be performed with larger number of patients and longer duration of follow up.
Asian journal of oncology, Jul 1, 2016
Comparison of the outcomes between locally advanced cervical squamous cell carcinoma and adenocar... more Comparison of the outcomes between locally advanced cervical squamous cell carcinoma and adenocarcinoma patients treated with definitive chemoradiation
Radiation oncology journal, Dec 31, 2018
Surgical excision along with use of postoperative radiotherapy forms an integral management of si... more Surgical excision along with use of postoperative radiotherapy forms an integral management of sinonasal teratocarcinosarcoma (SNTCS). However, given the rarity of the tumor, no standardised guidelines, dose, technique and target delineation exist especially in the era of modern radiation delivery techniques. This is a case of 55-year-old male diagnosed as SNTCS treated with radical ethmoidectomy followed by volumetric modulated radiotherapy, showing good local control and acceptable toxicity profile.
Asian Pacific Journal of Cancer Prevention, Jul 1, 2022
Haresh et al., 2020). The COVID-19 pandemic has affected oncology patients at many levels. Apart ... more Haresh et al., 2020). The COVID-19 pandemic has affected oncology patients at many levels. Apart from the psychological stress caused by a cancer diagnosis and COVID-19
Annals of pancreatic cancer, May 1, 2024
Radiotherapy and Oncology, Aug 1, 2021
Indian Journal of Nuclear Medicine, Dec 31, 2022
Annals of Oncology, Sep 1, 2021
Radiotherapy and Oncology, Aug 1, 2021
Radiotherapy and Oncology, Dec 1, 2019
Radiotherapy and Oncology, Aug 1, 2021
Radiotherapy and Oncology, Aug 1, 2021
Radiotherapy and Oncology, Aug 1, 2021
Radiotherapy and Oncology, Aug 1, 2021
Radiotherapy and Oncology, Aug 1, 2021
International Journal of Radiation Oncology Biology Physics, Nov 1, 2021
PURPOSE/OBJECTIVE(S) The incidence of de-novo metastatic head and neck (mHNC) has increased over ... more PURPOSE/OBJECTIVE(S) The incidence of de-novo metastatic head and neck (mHNC) has increased over time with the use of more sensitive metastatic work-up. With early diagnosis and better systemic therapies, aggressive management of mHNC has led to next most logical step in the management; use of definitive locoregional radiotherapy (d-RT) for patient responding to systemic therapy MATERIALS/METHODS: The institutional database was reviewed from January 2015 - March 2018, 5,483 HNC patients were isolated. Forty-nine patients were identified with de-novo mHNC, of which data was available for 31. Survival-analysis with endpoints of overall survival (OS) and progression free survival (PFS) was done. RESULTS With a median follow-up of 15 months, the median OS and PFS for the entire cohort was 15 and 7 months, respectively. Median PFS and OS of patients receiving d-RT vs no d-RT was 18 (range 14.97 - 21.03) months vs 5 (range 3.52 - 6.48) months, P = 0.005 and 38 (range 8.40 - 67.60) months vs 9 (range 4.56 - 13.45) months, P = 0.002, respectively. Patients with extra-pulmonary metastases had worse median OS of 21 (range 0 - 44.15) months, P = 0.047. CONCLUSION De-novo mHNC is a less often encountered diagnoses. Patients with extra-pulmonary metastases tend to do worse. However, patients who initially respond to chemotherapy fair better especially with d-RT. A prospective trial for such a clinical scenario would be unlikely and more retrospective evidence is needed for confirming OS and PFS advantage of using d-RT in such a setting.
Radiotherapy and Oncology, 2020
Radiotherapy and Oncology, 2021
Radiotherapy and Oncology, 2021
Radiotherapy and Oncology, 2021
Asian journal of oncology, Jul 1, 2016
with CTRT in the patients of uterine cervix of a tertiary cancer care centre. Patients and Method... more with CTRT in the patients of uterine cervix of a tertiary cancer care centre. Patients and Methods: Retrospective study was performed in locally advanced/advance stage patients of cervix UTERI registered in the institute between years 2009 to 2013. Patients were included in the two groups, group A consists of 89 patients who have received NACT + RS and 67 patients in group B who have received CTRT. Clinical records were reviewed with particular reference to presenting complaint, clinical stage, response to the therapy, disease free survival and overall survival. Statistical analysis was done using SPSS version 22. Results: In the neoadjuvant group (group A) (n=89) the median age of patients was 53 years (range 31-80 years), most of the patients (70%) were presented with complaint of postmenopausal bleeding. Of the total patients, 69 (77.5%) underwent to radical surgery and 5 (8.5%) received radiotherapy after NACT. From 69 patients, who had undergone to surgery, 54 (78.3%) had also received radiation. The overall response to induction chemotherapy was 84%. In the chemo radiation group (group B) (n=65) median age was 56 years (33-75 years). Vaginal bleeding (34%) followed by postmenopausal bleeding (32%) was major presenting complaint in this group. Overall response to the complete treatment was 91%. The median follow up time was 14.3 months in group A and 12.2 months in group B. The disease free survival for NACT group was 32 months (95% CI 26.8-36.5) whereas for CTRT group it was 28 months (95% CI 23.5-33) with 12 and 13 recurrences per group (p = .226). In NACT group overall survival was 46.2 months (95% CI 44-48.3) and for CTRT group it was 38.3 months (95%CI 36.6-40) with 3 and 2 deaths per group (p=.883). Conclusion: Present study shows comparable results, with no difference in survival between both the groups. However, NACT + RS group had showed better disease free and overall survival than another group. Further studies should be performed with larger number of patients and longer duration of follow up.
Asian journal of oncology, Jul 1, 2016
Comparison of the outcomes between locally advanced cervical squamous cell carcinoma and adenocar... more Comparison of the outcomes between locally advanced cervical squamous cell carcinoma and adenocarcinoma patients treated with definitive chemoradiation
Radiation oncology journal, Dec 31, 2018
Surgical excision along with use of postoperative radiotherapy forms an integral management of si... more Surgical excision along with use of postoperative radiotherapy forms an integral management of sinonasal teratocarcinosarcoma (SNTCS). However, given the rarity of the tumor, no standardised guidelines, dose, technique and target delineation exist especially in the era of modern radiation delivery techniques. This is a case of 55-year-old male diagnosed as SNTCS treated with radical ethmoidectomy followed by volumetric modulated radiotherapy, showing good local control and acceptable toxicity profile.
Asian Pacific Journal of Cancer Prevention, Jul 1, 2022
Haresh et al., 2020). The COVID-19 pandemic has affected oncology patients at many levels. Apart ... more Haresh et al., 2020). The COVID-19 pandemic has affected oncology patients at many levels. Apart from the psychological stress caused by a cancer diagnosis and COVID-19